Neurogene inc.NGNE.US Overview

US StockHealthcare

(No presentation for NGNE)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NGNE Overall Performance

NGNE AI Analysis & Strategy

NGNE Recent Performance

-2.84%

Neurogene inc.

0.81%

Avg of Sector

-1.14%

S&P500

NGNE PowerScanner

NGNE Key Information

NGNE Valuation Metrics

NGNE Earnings Table

NGNE Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.